Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing TransCon-based therapies for unmet medical needs in Denmark, rest of Europe, North America, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It also develops a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. Ascendis Pharma A/S was incorporated in 2006 and is headquartered in Hellerup, Denmark.

Ascendis Pharma A/S

Morgan Stanley analyst Maxwell Skor maintained a Buy rating on Ascendis Pharma today and set a price target of $240.50. According to TipRanks, Skor...

Morgan Stanley Remains a Buy on Ascendis Pharma (ASND)

An announcement from Ascendis Pharma ( ($ASND) ) is now available. On May 12, 2026, Ascendis Pharma A/S granted 31,250 new employee warrants, each ...

Ascendis Pharma Issues New Employee Warrants, Keeps Large Pool Available for Future Grants

Stifel Nicolaus analyst Alex Thompson CFA maintained a Buy rating on Ascendis Pharma on May 8 and set a price target of $328.00. The company’s shar...

Stifel Nicolaus Remains a Buy on Ascendis Pharma (ASND)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Ascendis Pharma (ASND) and Becton Dickinson (BDX) wi...

Analysts Are Bullish on These Healthcare Stocks: Ascendis Pharma (ASND), Becton Dickinson (BDX)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Prime Medicine, Inc. (PRME), Evolent Health (EVH) an...

Analysts Are Bullish on These Healthcare Stocks: Prime Medicine, Inc. (PRME), Evolent Health (EVH)

Ascendis Pharma ( ($ASND) ) just unveiled an update. Ascendis Pharma A/S on May 7, 2026 filed a Form 6-K reporting unaudited condensed consolidated...

Ascendis Pharma Swings to €629 Million Q1 2026 Profit on Strong Revenue Growth

The latest announcement is out from Ascendis Pharma ( ($ASND) ). Ascendis Pharma reported first-quarter 2026 revenue of €247 million, driven largel...

Ascendis Pharma Q1 2026 Results Highlight YORVIPATH Growth and U.S. Launch of YUVIWEL

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Ascendis Pharma (ASND) and Rhythm Pharmaceuticals (R...

Current Quarter	$0.19	Next Quarter	$0.63
Current Year	$4.54	Next Year	$10.8
QoQ Growth	+231.6%	YoY Growth	+137.9%
3Y EPS CAGR	+0.0%	Target Price	$291.88
Consensus	Buy	Upside	+22.9%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ASND	$237.47	+0.94%	295.74K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ASND	$237.47	+0.9%	295.74K
3
4
5
6

ASND

ASND

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Ascendis Pharma A/S Data in Excel

Get Ascendis Pharma A/S Data in Excel